Moderna (MRNA)
NASDAQ:MRNA
Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$53.72
-$4.21(-8.86%)
At close: 4:00 PM EST
$53.72
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $59.55
Previous CloseN/A
Volume7.58M
Average Volume (3M)6.43M
Market Cap
$21.57B
Enterprise Value$20.96B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 30, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding396,786,250
10 Day Avg. Volume5,890,728
30 Day Avg. Volume6,434,586
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue9.42
Enterprise Value/Gross Profit-67.82
Enterprise Value/Ebitda-7.09
Forecast
1Y Price Target
$41.75Price Target Upside-22.29% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-8.4
Revenue Forecast (FY)$2.08B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutPhase 3 adjuvant melanoma study for the individualized neoantigen vaccine is fully enrolled and well powered, making an interim efficacy readout a potential major upside catalyst if results mirror prior phase 2 outcomes.
Litigation And RoyaltiesSettlement removing future royalty obligations on the disputed COVID vaccine portfolio reduces a material litigation overhang and clarifies revenue attribution for unaffected products.
Regulatory Pathway For Flu VaccineFDA acceptance of the flu vaccine filing establishes a clear review pathway and reopens the opportunity to capture a portion of the older adult flu market, supporting revenue diversification away from COVID sales.
Bears Say
Appellate And Government Immunity RiskNarrow court interpretations of government-contractor immunity and the prospect of appeals leave contingent appellate risk that could result in additional payments and prolonged legal uncertainty.
Data Timing UncertaintyEvent-driven accrual requirements for the pivotal melanoma trial create timing uncertainty that could delay the key interim readout and extend investor uncertainty.
Patent Litigation ExposureMultiple active lawsuits and recent limits on invalidity defenses increase the risk of adverse rulings or recurring royalty obligations related to booster and delivery technologies, posing ongoing financial liability.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $59.55 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $21.57B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 30, 2026 which is in 81 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -$3.4 earnings per share for the quarter, beating the consensus estimate of -$4.446 by $1.046.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.06.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.4 in its last earnings report, beating expectations of -$4.446. Following the earnings report the stock price went down -1.241%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$41.75 (-22.29% Downside)
$41.75 (-22.29% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 92%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 55.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bearish
Bullish news 11%
Bearish news 89%
Bearish news 89%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.35%
12-Months-Change
Fundamentals
Return on Equity
-30.15%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$41.75
▼(-22.29% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.73% Insiders
26.52% Mutual Funds
7.26% Other Institutional Investors
36.24% Public Companies and Individual Investors